Mayflower Financial Advisors LLC Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mayflower Financial Advisors LLC lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 839 shares of the medical equipment provider’s stock after purchasing an additional 35 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Intuitive Surgical were worth $373,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the period. Capital World Investors grew its holdings in shares of Intuitive Surgical by 1.0% during the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares during the period. Edgewood Management LLC grew its holdings in shares of Intuitive Surgical by 7.9% during the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Intuitive Surgical by 4.6% during the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after purchasing an additional 198,483 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research analyst reports. Morgan Stanley raised their target price on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Barclays raised their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Evercore ISI lowered their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Truist Financial raised their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Finally, The Goldman Sachs Group initiated coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price for the company. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 239 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $416.60, for a total transaction of $99,567.40. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,293,799.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $416.60, for a total transaction of $99,567.40. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,656 shares of company stock valued at $24,700,644. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $476.69 on Friday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $493.97. The firm has a market capitalization of $169.08 billion, a PE ratio of 86.05, a price-to-earnings-growth ratio of 5.43 and a beta of 1.39. The stock’s 50-day simple moving average is $458.20 and its 200-day simple moving average is $417.34.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the company earned $1.18 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.